Back to top
more

Aurora Cannabis (ACB)

(Real Time Quote from BATS)

$5.06 USD

5.06
63,029

-0.03 (-0.59%)

Updated Oct 28, 2025 10:02 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.16%
3Hold10.10%
4Sell5.63%
5Strong Sell2.84%
S&P50011.45%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 243)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Medtronic (MDT) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Medtronic (MDT) delivered earnings and revenue surprises of 2.53% and 1.08%, respectively, for the quarter ended April 2025. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Aurora Cannabis Rides the Global Legalization Wave: Should You Invest?

by Urmimala Biswas

ACB capitalizes on the rapidly evolving medical cannabis landscape, leveraging its EU GMP-certified manufacturing facilities, advanced genetics and deep regulatory knowledge.

Zacks Equity Research

Are Medical Stocks Lagging Aurora Cannabis (ACB) This Year?

by Zacks Equity Research

Here is how Aurora Cannabis Inc. (ACB) and Concentra Group (CON) have performed compared to their sector so far this year.

Zacks Equity Research

Is Aurora Cannabis (ACB) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Aurora Cannabis Inc. (ACB) and AdaptHealth Corp. (AHCO) have performed compared to their sector so far this year.

Zacks Equity Research

Wall Street Analysts Predict a 25.67% Upside in Aurora Cannabis (ACB): Here's What You Should Know

by Zacks Equity Research

The mean of analysts' price targets for Aurora Cannabis (ACB) points to a 25.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Best Momentum Stocks to Buy for February 21st

by Zacks Equity Research

ACB, BHRB and BJ made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 21, 2024.

Zacks Equity Research

New Strong Buy Stocks for February 21st

by Zacks Equity Research

BHRB, ACB, MWA, BJ and PRTH have been added to the Zacks Rank #1 (Strong Buy) List on February 21, 2024.

Zacks Equity Research

Best Value Stocks to Buy for February 21st

by Zacks Equity Research

ACB, and PRTH made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 21, 2024.

Zacks Equity Research

All You Need to Know About Aurora Cannabis (ACB) Rating Upgrade to Strong Buy

by Zacks Equity Research

Aurora Cannabis (ACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Is Beam Therapeutics (BEAM) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Beam Therapeutics Inc. (BEAM) and Aurora Cannabis Inc. (ACB) have performed compared to their sector so far this year.

Zacks Equity Research

Aurora Cannabis Inc. (ACB) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Aurora Cannabis (ACB) delivered earnings and revenue surprises of 50% and 9.50%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Pre-Markets Soar after Trump Wins U.S. Presidential Election

by Zacks Equity Research

Pre-Markets Soar after Trump Wins U.S. Presidential Election

Mark Vickery headshot

Pre-Markets Surge on Historic Trump Victory

by Mark Vickery

The Dow is currently +1300 points, the S&P 500 +132, the Nasdaq +361 and the small-cap Russell 2000 +141 points.

Zacks Equity Research

Aurora Cannabis Inc. (ACB) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Aurora Cannabis (ACB) delivered earnings and revenue surprises of 118.18% and 11.97%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

GE HealthCare Technologies (GEHC) Tops Q3 Earnings Estimates

by Zacks Equity Research

GE HealthCare (GEHC) delivered earnings and revenue surprises of 7.55% and 0.02%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aurora Cannabis Stock Rises Following Medical Cannabis Oil Launch

by Zacks Equity Research

ACB and MedReleaf Australia launch premium medical cannabis oils, offering tailored cannabinoid formulations for patient care.

Zacks Equity Research

ACB Stock Likely to Gain From Genome BC-Funded Aroma Research Project

by Zacks Equity Research

Aurora Cannabis' new collaboration on the Genome BC-Funded Project addresses distinct cannabis aromas.

Zacks Equity Research

Aurora Cannabis Inc. (ACB) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aurora Cannabis (ACB) delivered earnings and revenue surprises of 68.57% and 20.16%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Stryker (SYK) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Stryker (SYK) delivered earnings and revenue surprises of 0.72% and 0.30%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aurora Cannabis Inc. (ACB) Surpasses Q4 Earnings Estimates

by Zacks Equity Research

Aurora Cannabis (ACB) delivered earnings and revenue surprises of 161.11% and 2.54%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

High Tide Inc. (HITI) Reports Break-Even Earnings for Q2

by Zacks Equity Research

High Tide (HITI) delivered earnings and revenue surprises of 100% and 2.73%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

SolGel Technologies (SLGL) delivered earnings and revenue surprises of -53.33% and 64.15%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in Canopy Growth (CGC): Can Its 11.0% Jump Turn into More Strength?

by Zacks Equity Research

Canopy Growth (CGC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks Equity Research

Rockwell Medical (RMTI) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rockwell Medical (RMTI) delivered earnings and revenue surprises of 60% and 7.06%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aurora Cannabis (ACB) Moves 46.0% Higher: Will This Strength Last?

by Zacks Equity Research

Aurora Cannabis (ACB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.